Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 12/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5157293 | 0.82 | HSD11B1 (0.56) | HSD11B1EPHX2CYP2D6ALDH1A1SMN1; SMN2 | |
| SCHEMBL5160289 | 0.74 | HSD11B1 (0.68) | HSD11B1EPHX2ALDH1A1 | |
| SCHEMBL5157584 | 0.73 | HSD11B1 (0.67) | HSD11B1EPHX2 | |
| SCHEMBL6344317 | 0.73 | HSD11B1 (0.74) | HSD11B1 | |
| SCHEMBL8549537 | 0.73 | EPHX2 (0.56) | HSD11B1EPHX2ALDH1A1SMN1; SMN2 | |
| SCHEMBL4230028 | 0.73 | EPHX2 (0.58) | HSD11B1EPHX2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL5154827 | 0.73 | HSD11B1 (0.70) | HSD11B1EPHX2ALDH1A1 | |
| SCHEMBL12640543 | 0.73 | HSD11B1 (0.77) | HSD11B1EPHX2 | |
| SCHEMBL6504402 | 0.72 | HSD11B1 (0.65) | HSD11B1EPHX2ALDH1A1 | |
| SCHEMBL6505342 | 0.72 | HSD11B1 (0.59) | HSD11B1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1745019-A1 | NOVEL COMPOUNDS OF PROLINE AND MORPHOLINE DERIVATIVES | PFIZER INC. (US) | 2007-01-24 | — | — | EP | disclosed |
| US-20050261290-A1 | Novel compounds of proline and morpholine derivatives | CHENG HENGMIAO | 2005-11-24 | — | — | US | disclosed |
| WO-2005108359-A1 | NOVEL COMPOUNDS OF PROLINE AND MORPHOLINE DERIVATIVES | PFIZER INC. (US) | 2005-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261290-A1 | Novel compounds of proline and morpholine derivatives | CYP11B1, HSD11B1, CYP11B2 | HSD11B1 2/4885EPHX2 2185/4885CYP2D6 296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.